Trials / Completed
CompletedNCT03873337
Persistence Targeted Smoking Cessation in Serious Mental Illness (SMI)
Persistence Targeted Smoking Cessation in Schizophrenia (PTSC-S)
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 34 (actual)
- Sponsor
- Rutgers, The State University of New Jersey · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Due to the pandemic, this study was modified from a randomized clinical trial to test the feasibility, initial efficacy, and mechanisms of action of our PTSC-S intervention to a feasibility and acceptability test of our intervention when delivered via telehealth in a single group, within-subjects design.
Detailed description
The investigators will test the feasibility and acceptability of a telehealth-delivered treatment designed to help smokers with serious mental illness to quit using a therapy approach focused on increasing task persistence. We will provide free, weekly individual telehealth video counseling sessions for 8 weeks and 10-weeks' worth of the nicotine transdermal patch (an FDA-approved smoking cessation product available over the counter). All sessions will be video recorded for treatment integrity and supervision. The investigators hypothesize that 1) the PTSC-S intervention will be acceptable to participants, and the study will be feasible to conduct. We will report prolonged and point prevalence abstinence rates at end-of-counseling and at 3-month follow-up (CO verified \<8ppm).
Conditions
- Tobacco Use
- Tobacco Smoking
- Tobacco Use Cessation
- Tobacco Use Disorder
- Schizophrenia
- Schizoaffective Disorder
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Persistence Targeted Smoking Cessation in SMI (PTSC-S) | All participants will receive 8 weeks of persistence focused smoking cessation counseling delivered via telehealth |
| DRUG | Nicotine patch | All participants will receive 10 weeks of nicotine patch |
Timeline
- Start date
- 2019-04-22
- Primary completion
- 2022-01-10
- Completion
- 2022-01-31
- First posted
- 2019-03-13
- Last updated
- 2022-09-13
- Results posted
- 2022-08-16
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03873337. Inclusion in this directory is not an endorsement.